Table 2

Pharmacodynamic effects of continuously intravenously infused blinatumomab on T- and B-cell kinetics in the first treatment cycle of MRD+ ALL patients

Mean ± SDRange
T cells
Time, d
        Time to T-cell nadir0.36 ± 0.240.06-1.09
        Time to 50% T-cell recovery3.13 ± 1.850.82-9.10
        Time to maximal T-cell increase17.57 ± 9.002.06-28.06
T cells/μL
        T-cell count at baseline532 ± 283112-1364
        T-cell count at nadir36 ± 492-197
        Maximal T-cell count during treatment1013 ± 430376-1954
        T-cell count at end of treatment737 ± 317152-1410
        T-cell count after 1-wk recovery period825 ± 432287-1599
T cells, %
        Maximal T-cell increase relative to baseline220 ± 12393-547
B cells
Time, d
        Time to B-cell depletion2.18 ± 3.800.03-13.94
B cells/μL
        B-cell count at baseline75 ± 1192-454
        B-cell count at end of treatment1 ± 10-4
        B-cell count after 1-wk recovery period1 ± 30-13
  • Mean values ± SD and ranges for 20 evaluable patients are shown.

  • MRD indicates minimal residual disease; and ALL, acute lymphoblastic leukemia.